Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

A pooled analysis revealed a loading-dose regimen, especially for patients receiving secukinumab 150 mg for PsA, increases the odds of disease improvement.

Secukinumab 300 mg May Improve PsA or Active Psoriasis More Than 150 mg

This post-hoc analysis of phase 3 data, using GRAPPA-recognized PsA domains, highlighted disease improvements following treatment with guselkumab.


Guselkumab Led to Improvements Over Several Psoriatic Arthritis Disease Domains

Despite these conclusions, this meta-analysis also showed that those receiving PDE4 inhibitors were the least likely to report adverse events.


IL-17A Inhibition Shown to be Superior for Biologic-Naïve Psoriatic Arthritis Patients

Philip J Mease, MD, highlights recent data comparing the safety and efficacy of bimekizumab with other DMARDs for the treatment of PsA. 

Philip J Mease, MD: Bimekizumab Demonstrates Favorable Efficacy Compared with Other DMARDs for PsA 

Patients with higher disease activity reported the highest perceived consequence of disease. 

Lower Socioeconomic Status Linked to Negative Illness Perception in Patients with Arthritis

This month’s rheumatology month in review showcases the efficacy of various medications for the treatment of psoriatic arthritis, underscores the importance of addressing workforce challenges, and explores non-pharmacological interventions.

Rheumatology Month in Review: March 2024

Dermatologist and rheumatologist Saakshi Khattri highlights the importance of screening psoriasis patients for psoriatic arthritis and how that may impact treatment decisions.

Screening for PsA and Selecting Right Biologic Therapy

At week 52, investigators noted an overall improvement of 93% in PASI scores from baseline. 

Tildrakizumab Significantly Improves Skin Symptoms in Moderate-to-Severe Psoriasis 

The selective, allosteric tyrosine kinase 2 inhibitor demonstrated significant and clinically meaningful improvements in PROs versus placebo in a phase 2 trial of patients with PsA.

Deucravacitinib Improves Patient-Reported Outcomes in Active Psoriatic Arthritis

These data highlight the changes observed in cytokine levels among both PsA treatment responders and non-responders.

Impact of TNFi, IL-17Ai Treatments on Psoriatic Arthritis Biomarkers

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.